Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Cellceutix Corporation (otcqb:CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that its lead antibiotic, Brilacidin(TM), demonstrated visually convincing wound healing properties in a recently completed experiment in a diabetic rat model.
As a small molecule mimetic of human host defense proteins, brilacidin has demonstrated antibacterial and tissue healing properties on barrier surfaces, such as skin and mucous membranes. Results from the diabetic rat study are consistent with these properties.
http://www.marketwatch.com/story/ce...abetic-foot-wound-and-ulcer-market-2014-05-19
As a small molecule mimetic of human host defense proteins, brilacidin has demonstrated antibacterial and tissue healing properties on barrier surfaces, such as skin and mucous membranes. Results from the diabetic rat study are consistent with these properties.
http://www.marketwatch.com/story/ce...abetic-foot-wound-and-ulcer-market-2014-05-19